We now know that long term infection with certain types of HPV is the main cause of cervical cancer. The Compass Trial is comparing HPV testing to the Pap smear for cervical cancer screening.
Overseas research has shown that a test for these HPV types is, in fact, a better cervical cancer screening test than the Pap smear.
Thank you for supporting cervical cancer research through your ongoing participation in the Compass Trial.
You are one of over 76,000 Australian women helping improve cervical cancer prevention.
Cervical cancer: World first research to refine screening process underway
30 May 2019
Australian women supporting cervical cancer research
5 June 2019
HPV screening is far more effective than Pap tests: results from world-first clinical trial
21 September 2017
Over 90 per cent of cervical cancers are preventable by vaccination
10 August 2017
Thank you for your participation in the Compass trial. Your support of the trial is providing important monitoring and quality information for the Renewal of the National Cervical Screening Program.
The Compass trial seeks to confirm with research evidence the modelled performance of HPV testing compared with cytology testing. This remains important and among vaccinated women is the first trial in the world undertaking this comparison.